2020-10-28
New Drug Development:
Focus on immune cell therapies (CAR-T、ADCV、DC-CIK、CIK、GDT)treating cancers and umbilical mesenchymal stem cell treating myocardial infarction, stroke, COVID-19 and other major diseases.
1.Core Technology Platform:
(1).Chimeric Antigen Receptor (CAR-T)
■ Patented anti-HLA-Gchimeric antigen receptor, which turn the HLA-G induced inhibitor to active immune signal, and lead to tumor cell mediated cytotoxicity.
■ The HLA-G protein expression of a normal cell is extremely low, no dangerous side effects occur in CAR001 treatment.
■ Patented suicide gene of iCas9, which avoid the occurrence of side effects on the cancer patient; the use of small molecule drug of AP20187 help terminate cell drug CAR001 from cytotoxicity。
(2).Dendritic Cells (DC)
■ Ever Supreme had unique technology in isolating and developing cancer cells with specificity.
■ Technology on development of tumor-specific antigen.
■ low rejection and side effects.
■ Research team found that GBM patient with PD-1+/CD8+ratio lower than 0.21 has overall survival rate extended from 20 months to 60.97 months.
(3). Combined Therapy of Dendritic Cells and CIK Cells (DC-CIK)
■ Optimization of manufacturing process, DC and CIK can be co-cultured within two weeks.
■ Customized therapy, which does not affect therapy that the patient is already received, and provides much flexibility for treatment.
■ Patients who have received DC-CIK therapy for treating Stage IV hepatoma, tumor markers is maintained within normal range, no deterioration.
(4). Cytokine-Induced Killer (CIK) Cell
■ Contains NKT cells (CD3+ CD56+) and NK cells (CD3- CD56+) in combination.
■ Not restricted by major histocompatibility complex (MHC); when a patient is failed to retrieve the tumor tissues, CIK cells may be produced and carry out for effective cell therapy.
■ Except the use of Interleukin 2 (IL-2), unique process are applied to maintain tumor cell mediated cytotoxicity in culturing technology。
■ Effective cytotoxicity of CIK cell on GBM cells. (Note:Data from Ever Supreme R&D)。
(5).Gamma Delta T (GDT) Cells
GDT cells attack cancer cells by identifying multiple antigen, including transmembrane protein, cell adhesion molecules, and compounds in the frequently-seen cancer cells (Isopentenyl pyrophosphate IPP).
2.Stem Cell Technology Platform:
(1).Allogenic Umbilical Mesenchymal Stem Cells (UMSC) treatment of Acute Myocardial infarction(AMI).
(2).Allogenic Umbilical Mesenchymal Stem Cells (UMSC) treatment for Stroke.
(3). Allogenic Umbilical Mesenchymal Stem Cells for Treating COVID-19
Look for:
Product licensing, Joint-Venture, Strategic Alliance, Sales & Distribution
Booth No. M804